Abstract
Bisphosphonate (BPs) therapy has become a standard of care for patients with malignant bone disease. In addition, preclinical and preliminary clinical data suggest that BPs exert their direct or indirect antitumoral effects on cancer growth factor release, on cancer cell adhesion, invasion and viability, on cancer angiogenesis and on cancer cell apoptosis. Here, after a brief analysis on clinical indications, on the last generation amino-bisphosphonates (N-BP) and on biochemical pathways as molecular targets of BPs, we will discuss the molecular mechanisms of these antitumor effects. Recent evidence suggests that part of the antitumor activity of bisphosphonates may be attributed to an antiangiogenic effect. For this reason, we will analyse all the in vitro and in vivo preclinical reports and the first clinical evidence of antiangiogenic activity exerted by this class of drugs. Several patents have been reported in the review, considering the recents activities observed for these drugs. Taking together all the major results obtained in the described studies, it is possible to affirm that BPs, particularly zoledronic acid and pamidronate, could potentially represent a very powerful tool for angiogenesis inhibition leading to a better control of cancer growth and progression. The translation into the clinical setting of the preclinical evidence of an antiangiogenic power of these drugs is becoming an imperative need and should represent the objective of future clinical trials.
Keywords: Amino-bisphosphonates, angiogenesis, anti-cancer effects
Recent Patents on Anti-Cancer Drug Discovery
Title: Last Generation of Amino-Bisphosphonates (N-BPs) and Cancer Angiogenesis: A New Role for These Drugs?
Volume: 1 Issue: 3
Author(s): Daniele Santini, Gaia Schiavon, Silvia Angeletti, Bruno Vincenzi, Simona Gasparro, Claudia Grilli, Annalisa La Cesa, Vladimir Virzi, Valentina Leoni, Alfredo Budillon, Santolo R. Addeo, Michele Caraglia, Giordano Dicuonzo and Giuseppe Tonini
Affiliation:
Keywords: Amino-bisphosphonates, angiogenesis, anti-cancer effects
Abstract: Bisphosphonate (BPs) therapy has become a standard of care for patients with malignant bone disease. In addition, preclinical and preliminary clinical data suggest that BPs exert their direct or indirect antitumoral effects on cancer growth factor release, on cancer cell adhesion, invasion and viability, on cancer angiogenesis and on cancer cell apoptosis. Here, after a brief analysis on clinical indications, on the last generation amino-bisphosphonates (N-BP) and on biochemical pathways as molecular targets of BPs, we will discuss the molecular mechanisms of these antitumor effects. Recent evidence suggests that part of the antitumor activity of bisphosphonates may be attributed to an antiangiogenic effect. For this reason, we will analyse all the in vitro and in vivo preclinical reports and the first clinical evidence of antiangiogenic activity exerted by this class of drugs. Several patents have been reported in the review, considering the recents activities observed for these drugs. Taking together all the major results obtained in the described studies, it is possible to affirm that BPs, particularly zoledronic acid and pamidronate, could potentially represent a very powerful tool for angiogenesis inhibition leading to a better control of cancer growth and progression. The translation into the clinical setting of the preclinical evidence of an antiangiogenic power of these drugs is becoming an imperative need and should represent the objective of future clinical trials.
Export Options
About this article
Cite this article as:
Santini Daniele, Schiavon Gaia, Angeletti Silvia, Vincenzi Bruno, Gasparro Simona, Grilli Claudia, La Cesa Annalisa, Virzi Vladimir, Leoni Valentina, Budillon Alfredo, Addeo R. Santolo, Caraglia Michele, Dicuonzo Giordano and Tonini Giuseppe, Last Generation of Amino-Bisphosphonates (N-BPs) and Cancer Angiogenesis: A New Role for These Drugs?, Recent Patents on Anti-Cancer Drug Discovery 2006; 1 (3) . https://dx.doi.org/10.2174/157489206778776989
DOI https://dx.doi.org/10.2174/157489206778776989 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting the Type I Insulin-Like Growth Factor System for Breast Cancer Therapy
Current Drug Targets Astatine Radiopharmaceuticals: Prospects and Problems
Current Radiopharmaceuticals Quadruplex-Forming Oligonucleotides as Tools in Anticancer Therapy and Aptamers Design: Energetic Aspects
Current Medicinal Chemistry - Anti-Cancer Agents Regulation of Cell Migration and Invasion by Specific Modules of uPA: Mechanistic Insights and Specific Inhibitors
Current Drug Targets Epigenetic Remodeling of Chromatin Architecture: Exploring Tumor Differentiation Therapies in Mesenchymal Stem Cells and Sarcomas
Current Stem Cell Research & Therapy An Overview on the Role of miR-451 in Lung Cancer: Diagnosis, Therapy, and Prognosis
MicroRNA Ruthenium(II) Complexes as Potential Apoptosis Inducers in Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Effect of Intestinal Flora Clearance on Liver Proteomics in Mice
Current Proteomics Beta-Caryophyllene Suppresses Ovarian Cancer Proliferation by Inducing Cell Cycle Arrest and Apoptosis
Anti-Cancer Agents in Medicinal Chemistry The use of Azoles Containing Natural Products in Cancer Prevention and Treatment: An Overview
Anti-Cancer Agents in Medicinal Chemistry The Intriguing Interplay Between Therapies Targeting the Epidermal Growth Factor Receptor, the Hypoxic Microenvironment and Hypoxia-inducible Factors
Current Pharmaceutical Design Recent Progress in the Development of Natural ent-Kaurane Diterpenoids with Anti-tumor Activity
Mini-Reviews in Medicinal Chemistry Anti-Cancer Therapeutic Approaches Based on Intracellular and Extracellular Heat Shock Proteins
Current Medicinal Chemistry Structure, Roles and Inhibitors of a Mitotic Protein Kinase Haspin
Current Medicinal Chemistry Chemical Biology: Past, Present and Future
Current Chemical Biology Cartilage Regeneration Using Adipose-Derived Stem Cells
Current Stem Cell Research & Therapy DNAzyme Delivery Approaches in Biological Settings
Current Medicinal Chemistry Application of Microdialysis in Clinical Pharmacology
Current Clinical Pharmacology Kisspeptin Mediated Signaling in Cancer
Current Topics in Medicinal Chemistry Patent Selections
Recent Patents on Biomarkers